Revised guidelines that no longer favor prostate cancer screening using the prostate-specific antigen (PSA) test, issued in 2012, have resulted in a decrease in PSA screenings among men age 75 or older but not in overall prostate cancer screening rates. These findings, part of a study titled "Contemporary national trends of prostate cancer screening among privately insured patients in the United States," were presented at the American Society of Clinical Oncology's (ASCO) 2015 meeting in Chicago, Illinois. “With the most recent changes in 2012, the U.S. Preventive Services Task Force (USPSTF) essentially recommended against screening any men for prostate cancer with a digital rectal exam or PSA for men of average risk of getting prostate cancer. They gave it a grade D recommendation,” Simon Kim, MD, MPH, assistant professor of urology and urologic oncology at University Hospital Case Medical Center and Case Western Reserve University School of Medicine in Cleveland, Ohio, and a study investigator, said in a news release. “[There were] two trials that showed really mixed level evidence [regarding screening]. I think the controversy is because one trial showed no benefit and the other did.” The population-based data was taken from Optum Labs Data Warehouse, a database from private health insurance claims.